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Abstract 
In 2012, a 50 year-old athletic male presented with weakness, pain and unilateral phrenic 
paralysis, followed by bilateral phrenic paralysis with deep dyspnea. In 2013, the Parsonage-
Turner syndrome was diagnosed. When the patient was seen in September 2014 for the first 
time, he was facing phrenic neuromuscular failure, which led to the hypothesis of neurotropic 
herpes viruses. A control of the global serological anti-Herpes immunity to analyze his anti-
body (Ab) levels confirmed herpes immune genetic deficiency. An appropriate herpes chem-
otherapy treatment was proposed. Immediately, a spectacular recovery of the patient was 
observed, and after a few weeks, the respiratory function tests showed normal values. The 
hypothesis of the inductive role of viruses of the herpes family in the Parsonage-Turner syn-
drome was thus substantiated. The patient’s immune deficiency covers the HSV2, HHV3, 
HHV4, HHV5 and HHV6 Ab levels. This led to the control of herpes in the family lineage: in-
deed, his daughter presented alterations of her serological herpes Ab levels. 
© 2015 S. Karger AG, Basel 
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Introduction 
Parsonage-Turner is a clinically defined neuralgic amyotrophic syndrome. Affected pa-
tients present a characteristic pain followed by flaccid paralysis of some muscles, with an 
incidence peak between 30 and 50 years of age and a slight male predominance. The etiology 
remains unknown [1]. ‘Parsonage-Turner is notoriously unrecognized and is usually diag-
nosed with delay’, as reported by Verhasselt et al. [2]. 
Case Presentation 
Here we report the case of a 50-year-old athletic male who regularly participated in 
marathon competitions. In 2012, he presented with a unilateral phrenic paralysis, followed 
by a bilateral phrenic paralysis in 2013 that has persisted until today. The related clinical 
observations were a very deep dyspnea, disability to work, sleep disorder, neuropathic pain 
and weakness. In 2014, the Parsonage-Turner syndrome was diagnosed [3]. 
Respiratory function tests revealed a deep pulmonary deficiency; the patient’s great 
weakness remains his inability to climb stairs [4]. The essential muscular respiratory exer-
cises were followed daily with a physiotherapist. This patient, as all other adults with the 
Parsonage-Turner syndrome, has been followed for the past 2 years by neurologists, pneu-
mologists and immunologists who attempted to identify the causes of the syndrome. At the 
beginning, the treatment was symptomatic. The patient was treated with corticosteroids, 
analgesic drugs and physical therapy. 
He felt absolutely exhausted and hopeless when he was first seen in dermatological con-
sultation to treat a facial skin tumor. It is important to underline that looking at the blood 
analysis, a lasting monocytosis of >10% (standard: 3–5%) for the last 2 years was a warning 
of a possible viral infection. As scientists involved in virology and immunology related to 
cancer research and facing a neuromuscular failure, this suggested the idea of the potential 
occurrence of a neurotropic virus, but what kind of neurotropic virus remained to be seen. 
Herpes viruses were the first eligible, since the sensory nerves are almost invariably the 
target cells, and motor neurons may be involved in herpes diseases. As the patient has never 
been to tropical areas, other rare exotic tropical neurotropic viruses such as rhabdoviruses, 
arenaviruses, flaviviruses, bunyaviruses, togaviruses and paramyxoviruses did not need to 
be considered further. 
As stated recently by Marvisi et al. [5], ‘viral infections have been identified as the most 
likely etiology and in some cases a genetic mechanism may be involved’. Gariani et al. [6], 
examining a herpetic rash with an acute left shoulder pain and a simultaneous limb 
monoparesis, attributed these features to the Parsonage-Turner syndrome and questioned: 
could it be a herpes zoster neuropathy? Chebbi et al. [7] described a similar relationship 
between varicella-zoster infection followed by weakness, sensory symptoms, motor deficits 
and pain; the Parsonage-Turner syndrome followed a varicella-zoster virus infection. Conse-
quently, for the last 4 years, neurologists have postulated the involvement of herpes viruses 
in the Parsonage-Turner syndrome but without providing proof and/or anti-herpes therapy 
to cure this infection. 
The diagnosis led to the hypothesis of herpes as a genetic immune deficiency. A serolog-
ical evaluation was requested for all herpes viruses: human herpes virus 3 (HHV3), also 
known as varicella-zoster virus (VZV); herpes simplex virus 1 and 2 (HSV1/HSV2); human 
herpes virus 4 (HHV4), also known as Epstein-Barr Virus (EBV); human herpes virus 5 
(HHV5), also known as cytomegalovirus (CMV); human herpes virus 6 (HHV6), also known 
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as roseolovirus, and human herpes virus 8 (HHV8) (table 1). Many large serological anoma-
lies were found, confirming the hypothesis of a herpes genetic immune deficiency. 
As a first step and awaiting the results of the herpes serological evaluation (1 week), the 
patient started a daily non-herpes-specific treatment: retinol DCI (vitamin A 313): 50,000 
international units (IU) × 1 pill/day × 8 days; vitamin D3: 2,000 IU, 50 µg = 10 drops/day × 1 
month, and niacinamide (vitamin B3): 500 mg × 1 pill/day × 3 weeks. One week later, after 
receiving the herpes viral serology results, the patient started the classical herpes chemo-
therapy with valacyclovir: 500 mg × 2 pills/day × 5 days (an equivalent chemotherapy as 
used below would be acyclovir: 200 mg × 5 pills/day × 5 days). After a few days of appropri-
ate treatment, the patient reported that he was recovering day after day: ‘for the first time 
after 2 years, I am able to drink a glass of wine’ (very important for a French patient). Con-
stant revival followed: his pain disappeared, he recovered his sleep and his breath and was 
able to climb stairs, experiencing week after week the pleasure of recovering his health after 
2 years of terrible discomfort. 
Discussion 
It was necessary to focus on herpes as a genetic immune deficiency in the family lineage. 
The family history revealed that the father and mother did not have any kind of herpes dis-
ease. The patient’s children, two girls and one boy (20, 15 and 12 years old, respectively), 
were examined. Only the 15-year-old girl presented alterations of the serological herpes 
balance as had her father; she started with a mononucleosis infection diagnosed in May 
2014. She felt totally exhausted but received no treatment until her consultation at the der-
matological office in September 2014. It was decided to control her genetic immune status 
with regard to herpes and to compare it with that of her father. 
The serological herpes immunoglobulin G (IgG) blood controls showed the genetic im-
mune deficiency of the father concerning the HSV/HHV antibody (Ab) levels for HSV2, HHV3, 
HHV4, HHV5 and HHV6. Differences between the father and his daughter were observed in 
particular in the IgG levels to the Epstein-Barr nuclear antigen (EBNA HHV4) and the viral-
capsid antigen (VCA HHV4). The EBNA HHV4 IgG levels of the daughter were negative and 
unmodified by the infectious mononucleosis compared to her elevated VCA HHV4 IgG levels, 
while the father presented both elevated VCA and EBNA HHV4 IgG levels. Did this suggest 
that the daughter was unscathed of the genetic immune defect of the father?  
Both the father and his daughter presented unusually high titers of anti-HHV3 Abs, alt-
hough this Ab response was not neutralizing.  
Concerning the HHV4 Ab levels, the father’s serological IgG blood controls showed an 
unexpected genetic immune deficiency: the VCA IgG level was 727 IU/ml on September 3, 
2014, and showed a very important decrease after anti-VZV therapy and vaccination. On 
October 22, 2014, the level decreased to an unexpected level of 46 IU/ml, but when repeated 
on December 17, 2014, the VCA IgG level was 701 IU/ml, thus similarly high as the level ob-
served on September 3, 2014. The EBNA IgG level was elevated and remained unmodified 
due to administration of the anti-VZV therapy and the anti-VZV vaccination; before it, the 
level was 166 IU/ml and increased to 182 IU/ml. What is the prognosis of elevated HHV4? 
We do not know how the future of the patient holds for him. 
The daughter already presented infectious mononucleosis in May 2014 but received no 
treatment. Compared to the father, there was an interesting difference between her EBV VCA 
and EBNA IgG Ab levels. The VCA IgG level was highly positive after two controls: 171 IU/ml 
(May 2014) and 282 IU/ml (September 2014), while the EBNA IgG level was negative when 
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controlled twice (3 IU/ml). The daughter with her mononucleosis infection has not been 
affected by the deep EBNA genetic immune defect of her father (table 1). 
In October 2014, the prescription for the daughter was the same non-herpes-specific 
treatment as for the father: retinol DCI (vitamin A 313): 50,000 IU × 1 pill/day × 8 days; ni-
acinamide (vitamin B3): 500 mg × 1 pill/day × 3 weeks, and anti-herpes chemotherapy with 
acyclovir: 1,000 mg/day × 5 days (usual dose). In agreement with the father, it was decided 
to propose anti-VZV vaccination 3–4 weeks later to enhance the efficiency of her herpes de-
fense ability. Vaccination has to be followed by an anti-VZV booster vaccination [8] (accord-
ing to the classical CDC Atlanta protocol for children) 3–6 months later. A few weeks after 
the treatment and anti-VZV vaccination, the adolescent quickly recovered. 
At the end of October 2014, week after week, the father noticed the efficiency of the 
herpes disease treatment, which corroborated the assumption of the herpes viral etiology. 
The most recent control of the respiratory function showed normal results compared to 
those of June 2014. On June 30, 2014, a bilateral diaphragmatic paresis respiratory control 
showed a 30% decrease in vital capacity. On October 24, 2014, checking this diaphragmatic 
phrenic nerve paralysis, the functional respiratory tests revealed a normal respiratory func-
tion.  
Conclusion 
Our results revealed a potential inductive role of members of the herpes virus family in 
the Parsonage-Turner syndrome. It is possible to conclude with a therapeutic proposal, 
which has proved successful in our patient. After the serological herpes Ab controls, a classi-
cal anti-herpes therapy was proposed. As a first step, acyclovir or valacyclovir to cure the 
herpes infection were administered. Three to four weeks later, anti-VZV vaccination to pre-
vent any relapse of herpes infection was delivered given the genetic immune defect of the 
patient. One question still remains to be answered: is it possible to find a long-term cure to 
correct a herpes immunological defect? A booster anti-VZV vaccine has been proposed as a 
necessary complementary therapy 2–3 months later. In the future, the HHV3 and HHV4 se-
rological Ab levels of the patient will be evaluated once a year, as they are early markers of 
all kinds of evolutionary diseases linked to herpes viruses. 
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Table 1. Serological IgG blood controls: immuno-luminometric assay (IU/ml) 
        
        
 HSV1 HSV2 HHV3 
VZV 
HHV4 
EBV 
HHV5 
CMV 
HHV6 HHV8 
        
        
Father (born in 1964) 
Parsonage-Turner: 2012–2015 
September 3, 2014: no treatment 
<0.9 (–) >8.0 (+) 2,069 (++) VCA 727 (+++)  
EBNA 166 (++) 
90.3 (+) 20 (+) (–) 
                October 7, 2014: anti-VZV vaccination        
                October 22, 2014: 
after anti-VZV vaccination 
<0.9 (–) >8.0 (+) 3,133 (++) VCA 46 (+)  
EBNA 182 (++) 
101 (+) 40 (+) (–) 
                December 17, 2014   2,339 (++) VCA 701 (+++)  
EBNA 147 (++) 
   
                Daughter (born 1998) 
May 9, 2014: infectious 
mononucleosis, no treatment 
   VCA 171 (++) 
EBNA 3 (–) 
105 (+)   
                September 29, 2014: no treatment <0.9 (–) <0.9 (–) 2,511 (++) VCA 282 (+++)  
EBNA 3 (–) 
124 (+) 40 (+) (–) 
                November 11, 2014: 
anti-VZV vaccination 
2015: serodiagnosis expected 
       
        
        
Analysis of the serological herpes Ab qualitative and quantitative values. 
HHV3 (VZV) standard = ±1,500 IU/ml. Normal values related to the usual values. Positive to highly positive (++)/(+++) = 
higher values related to the usual values. (–) = Lower values related to the usual values. HHV4 (EBV): EBNA = Epstein-Barr 
nuclear antigen; VCA = Epstein-Barr viral capsid antigen. 
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